PRIMARY STUDY
Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer
Key Findings: This study of looking at alterations in the endocannabinoid system of patients with inflammatory bowel disease (IBD), Crohn's Disease (CD) colorectal cancer (CRC) finds distinct differences in levels of endocannabinoid compared to control patients. In CD oleoylethanolamide (OEA) and 2-arachidonoylglycerol (2-AG) appear to be involved. In IBD lysophosphatidylinositol (LPI) seems to be pro-inflammatory. In CRC 2-AG is elevated, and in UC and CD anandamide (AEA), palmitoylethanolamide (PEA) and OEA were increased.
Type of Study: Clinical Trial
Study Sample Size: 63
Study Result: Positive
Research Location(s): Austria, Germany
Year of Pub: 2019
Cannabinoids Studied: Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Other Related Compounds, Lysophosphatidylinositol (LPI), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, GPCR, TRPs, PPARs
Citation: Grill M, et al. Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. Sci Rep. 2019; 9:2358. doi: 10.1038/s41598-019-38865-4
Authors: Grill M, Högenauer C, Blesl A, Haybaeck J, Golob-Schwarzl N, Ferreirós N, Thomas D, Gurke R, Trötzmüller M, Köfeler HC, Gallé B, Schicho R
